IceCure Medical Enters into an Exclusive Agreement in Poland for Distribution of the ProSense™ Cryoablation System
Retrieved on:
Wednesday, October 20, 2021
Freezing, Cancer, Woman, Technology, Form, Private Securities Litigation Reform Act, Kidney, Neoplasm, European Union, Awareness, Lung, Breast cancer, Breast, Calamochrous minimalis, Nasdaq, FDA, Risk, CE, Patient, Health, Mobile, Union, SEC, TASE, Solution, Environment, Company, Pharmaceutical industry, Medical imaging, Mobile phone
("Mobile SCANMED Systems") to exclusively sell the Company's ProSense Cryoablation System and disposables in Poland.
Key Points:
- ("Mobile SCANMED Systems") to exclusively sell the Company's ProSense Cryoablation System and disposables in Poland.
- Within twelve months of signing the initial distribution agreement, the parties expect to enter into a long-term exclusive distribution agreement.
- Today's agreement will bring the ProSense Cryoablation System's innovative cryoablation technology to breast cancer patients across Poland.
- Under the terms of the initial distribution agreement, Mobile SCANMED Systems shall be responsible to address all requirements to sell the ProSense Cryoablation System in Poland.